• Client Login
Ozmosi
  • Services
    • BEAM Clinical Trial Data
    • GCT Global Clinical Trials
    • PRYZM Pharma Product Database
    • PDUFA Calendar
    • KRYSTL Industry Scan Reporting
    • LENZ Company Pipeline Summary
    • Specialized Consulting
    • Approved Pharmaceutical Products in Use
  • About Us
  • Case Studies
  • Newsroom
  • Contact Us
Select Page
Merck Diabetes Pipeline Analysis

Merck Diabetes Pipeline Analysis

Aug 25, 2025 | Business, Data Analytics, Diabetes, Disease Area Trends

Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....

Recent Posts

  • Uncovering New Catalyst Events in the Pharmaceutical and Biotech MarketsAugust 28, 2025
  • China Reshaping the Clinical Trial PipelineAugust 28, 2025
  • Finding the Needle in a Haystack with NLPAugust 28, 2025
  • Using Data to Optimize Clinical Trial RecruitmentAugust 28, 2025
  • Healthiest States Index of The USA 2024August 28, 2025
  • New Developments in Alzheimer’s TreatmentAugust 28, 2025
  • Home
  • About Us
  • Services
  • Case Studies
  • Newsroom
  • Contact Us
  • Facebook
  • X
OZMOSI© 2025 | All Rights Reserved | Site by Webtyde